These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 8303945)

  • 21. An evaluation of the safety and immunogenicity of a five-component acellular pertussis, diphtheria, and tetanus toxoid vaccine (DTaP) when combined with a Haemophilus influenzae type b-tetanus toxoid conjugate vaccine (PRP-T) in Taiwanese infants.
    Lee CY; Thipphawong J; Huang LM; Lee PI; Chiu HH; Lin W; Debois H; Harrison D; Xie F; Barreto L
    Pediatrics; 1999 Jan; 103(1):25-30. PubMed ID: 9917435
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. Progetto Pertosse Working Group.
    Greco D; Salmaso S; Mastrantonio P; Giuliano M; Tozzi AE; Anemona A; Ciofi degli Atti ML; Giammanco A; Panei P; Blackwelder WC; Klein DL; Wassilak SG
    N Engl J Med; 1996 Feb; 334(6):341-8. PubMed ID: 8538704
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of schedule on reactogenicity and antibody persistence of acellular and whole-cell pertussis vaccines: value of laboratory tests as predictors of clinical performance.
    Miller E; Ashworth LA; Redhead K; Thornton C; Waight PA; Coleman T
    Vaccine; 1997 Jan; 15(1):51-60. PubMed ID: 9041666
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dose-response to a two-component acellular pertussis vaccine in infants and comparison with whole-cell vaccine.
    Auerbach BS; Lake AM; Wilson ME; Willingham FF; Shematek J; Moulton L; Deforest A; Halsey NA
    Biologicals; 1998 Jun; 26(2):145-53. PubMed ID: 9811522
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunogenicity and reactogenicity of a single dose of a diphtheria--tetanus--acellular pertussis component vaccine (DTaP) compared to a diphtheria--tetanus toxoid (Td) and a diphtheria toxoid vaccine (d) in adults.
    Bartels I; Jüngert J; Lugauer S; Stehr K; Heininger U
    Vaccine; 2001 Apr; 19(23-24):3137-45. PubMed ID: 11312009
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of a diphtheria and tetanus toxoids and bicomponent acellular pertussis vaccine with diphtheria and tetanus toxoids and whole-cell pertussis vaccine in infants.
    Pichichero ME; Francis AB; Marsocci SM; Green JL; Disney FA
    Am J Dis Child; 1993 Mar; 147(3):295-9. PubMed ID: 8438811
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Reactogenicity and immunogenicity of a three-component acellular pertussis vaccine administered as the primary series to 2, 4 and 6 month old infants in the United States.
    Bernstein HH; Rothstein EP; Pichichero ME; Green JL; Reisinger KS; Blatter MM; Halpern J; Arbeter AM; Bernstein DI; Smith V
    Vaccine; 1995 Dec; 13(17):1631-5. PubMed ID: 8719512
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combined tetanus, diphtheria, and 5-component pertussis vaccine for use in adolescents and adults.
    Pichichero ME; Rennels MB; Edwards KM; Blatter MM; Marshall GS; Bologa M; Wang E; Mills E
    JAMA; 2005 Jun; 293(24):3003-11. PubMed ID: 15933223
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Study of pertussis vaccines in infants: comparison of response to acellular pertussis DTP vaccines containing 25 micrograms of FHA and either 25 or 8 micrograms of PT with response to whole-cell pertussis DTP vaccine.
    Vanura H; Just M; Ambrosch F; Berger RM; Bogaerts H; Wynen J; Vandevoorde D; Wiedermann G
    Vaccine; 1994; 12(3):210-4. PubMed ID: 8165852
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A randomized comparison of reactogenicity and immunogenicity of two whole-cell pertussis vaccines.
    Steinhoff MC; Reed GF; Decker MD; Edwards KM; Englund JA; Pichichero ME; Rennels MB; Anderson EL; Deloria MA; Meade BD
    Pediatrics; 1995 Sep; 96(3 Pt 2):567-70. PubMed ID: 7659477
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A randomized controlled trial of two acellular pertussis-diphtheria-tetanus vaccines in primary immunization in Ghana: antibody responses and adverse reactions.
    Hori H; Afari EA; Akanmori BD; Kamiya Y; Sakatoku H; Nkrumah FK; Kamiya H; Chazono M; Fukai K
    Ann Trop Paediatr; 1994; 14(2):91-6. PubMed ID: 7521636
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Simultaneous administration of a diphtheria and tetanus toxoids and acellular pertussis vaccine with measles-mumps-rubella and oral poliovirus vaccines.
    Rothstein EP; Bernstein HH; Glode MP; Laussucq S; Nonenmacher J; Long SS; Hackell JG
    Am J Dis Child; 1993 Aug; 147(8):854-7. PubMed ID: 8394646
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dose-response to acellular pertussis vaccine and comparison with whole cell pertussis vaccine at 15-24 months and 4-6 years of age. Acellular Pertussis Vaccine Study Team.
    Auerbach BS; Wilson ME; Lake AM; Deforest A; Steinhoff M; Halsey NA
    Vaccine; 1992; 10(1):14-20. PubMed ID: 1539456
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of gender, race, and parental education on immunogenicity and reported reactogenicity of acellular and whole-cell pertussis vaccines.
    Christy C; Pichichero ME; Reed GF; Decker MD; Anderson EL; Rennels MB; Englund JA; Edwards KM; Steinhoff MC
    Pediatrics; 1995 Sep; 96(3 Pt 2):584-7. PubMed ID: 7659481
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Acellular and whole-cell pertussis vaccines as booster doses: a multicenter study.
    Englund JA; Decker MD; Edwards KM; Pichichero ME; Steinhoff MC; Anderson EL
    Pediatrics; 1994 Jan; 93(1):37-43. PubMed ID: 8265321
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A search for serologic correlates of immunity to Bordetella pertussis cough illnesses.
    Cherry JD; Gornbein J; Heininger U; Stehr K
    Vaccine; 1998 Dec; 16(20):1901-6. PubMed ID: 9796041
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Acellular pertussis vaccines in infants: evaluation of single component and two-component products.
    Anderson EL; Mink CM; Berlin BS; Shih CN; Tung FF; Belshe RB
    Vaccine; 1994 Jan; 12(1):28-31. PubMed ID: 8303937
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety and immunogenicity of a combined Tetanus, Diphtheria, recombinant acellular Pertussis vaccine (TdaP) in healthy Thai adults.
    Sirivichayakul C; Chanthavanich P; Limkittikul K; Siegrist CA; Wijagkanalan W; Chinwangso P; Petre J; Hong Thai P; Chauhan M; Viviani S
    Hum Vaccin Immunother; 2017 Jan; 13(1):136-143. PubMed ID: 27686283
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Reactogenicity and immunogenicity of reduced antigen content diphtheria-tetanus-acellular pertussis vaccines as a booster in 4-7-year-old children primed with diphtheria-tetanus-whole cell pertussis vaccine before 2 years of age.
    Dagan R; Igbaria K; Piglansky L; Van Brusteghem F; Melot V; Kaufhold A
    Vaccine; 1999 Jun; 17(20-21):2620-7. PubMed ID: 10418911
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Differences in reactogenicity and antigenicity of acellular and standard pertussis vaccines combined with diphtheria and tetanus in infants.
    Anderson EL; Belshe RB; Bartram J
    J Infect Dis; 1988 Apr; 157(4):731-7. PubMed ID: 2894399
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.